Daidzein derivative daid002 inhibits glioblastoma growth via disrupting the interaction between moesin and CD44
Metrics: PDF 259 views | HTML 390 views | ?
Xin Zhang1, Xiuting Liu1, Jinghui Zhang1, Wei Zhou1, Jinrong Lu2, Qing Wang3 and Rong Hu1
1State Key Laboratory of Natural Medicines, Department of Physiology, China Pharmaceutical University, Jiangsu, Nanjing, 210009, China
2Department of Organic Chemistry, China Pharmaceutical University, Jiangsu, Nanjing, 210009, China
3Department of Neurosurgery, Wuxi Second Hospital Affiliated Nanjing Medical University, Jiangsu, Wuxi 214002, China
Qing Wang, email: email@example.com
Rong Hu, email: firstname.lastname@example.org
Keywords: glioblastoma; daid002; moesin; CD44
Received: August 29, 2017 Accepted: December 01, 2017 Published: January 11, 2018
Glioblastoma multiforme is a fatal brain tumor with very limited therapeutic options. Recently, an ezrin-radixin-moesin family protein, moesin, is reported to be positively correlated with higher grade of glioblastoma. Here, we reported that daid002, a novel daidzein derivative, inhibited glioblastoma growth and induced G0/G1 phase arrest. Daid002 decreased moesin phosphorylation through restraint of the direct interaction between moesin and CD44 on the cell membrane and reduced cyclin D1 expression via regulating nuclear translocation of β-catenin. In vivo, daid002 exerted a significant inhibition on glioblastoma growth through CD44/moesin signaling. Our findings established daid002 as an anti-glioblastoma agent by targeting CD44/moesin.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.